Vistagen Therapeutics Inc (VTGN) Stock Price, Quote & News

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical tria...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 577 3600

Website: www.vistagen.com

Address:

343 Allerton Avenue, South San Francisco, United States

Bulltrader988 Sep. 11 at 7:03 PM

$VTGN Next week 👃👀

0 · Reply

smooth2222 Sep. 11 at 6:47 PM

$VTGN Lets get a buyout for Refisolone, tia, all imo

0 · Reply

defineme44 Sep. 11 at 4:40 PM

$VTGN Lilly is clearly expanding into women’s health, while Vistagen's refisolone (PH80) is an FDA-cleared-to-proceed Phase 2 asset for menopausal hot flashes with encouraging earlier results. Vistagen is also looking at strategic opportunities for its pherine drugs, and its previous Fuji exclusivity has ended. Lilly's move increases the strategic value of women's-health assets like refisolone and potentially the pool of interested partners. There is currently no evidence Lilly and VTGN are actually talking, but the fit is worth watching.

0 · Reply

DYL2025 Sep. 11 at 4:29 PM

$VTGN bye bye fuji. hello lilly.

0 · Reply

SpartanTrader117 Sep. 10 at 7:11 PM

$SRXH $VTGN

0 · Reply

gapureau Sep. 10 at 6:56 PM

$VTGN Seen BioPharma stocks show nice moves on much less news than this upcoming presentation. Besides the study results that tanked the stock, pretty sure the main pressure recently has been the PR that SRX Global acquired a stake in the company a month or so back (although no details of what or how many shares). And, since Eric Jackson is absolutely "Loved" by his friends over at $SRXH, this stock is mention constantly in the "negative" post over there. Be interesting to hear/see what's presented next week. GLTA!

0 · Reply

MikeScottTradingCo Sep. 10 at 6:33 PM

$VTGN

0 · Reply

Bulltrader988 Sep. 10 at 6:16 PM

$VTGN "...today announced it will present data highlighting a positive efficacy signal for its Phase 3 product candidate, fasedienol nasal spray, in public speaking challenge study participants with very severe social anxiety disorder at Psych Congress in New Orleans on Thursday, September 17, and Friday, September 18, 2026... Poster Presentation Date: Thursday, September 17, 2026, and Friday, September 18, 2026 Title: Fasedienol Nasal Spray for Acute Treatment of Social Anxiety Disorder in Participants With Baseline LSAS Scores ≥95: Subgroup Analyses from Two Multi-center, Randomized, Placebo-controlled Public Speaking Challenge Trials Authors: Azmi Nasser, PhD, Michael R. Liebowitz, MD, Aubrey Reid, MS, Imogene Dunn, PhD, Eric Davis, MD, Ross A. Baker, PhD, Angel Angelov, MD, Louis Monti, MD, PhD Poster Number: 230..." 👃👀 https://www.stocktitan.net/news/VTGN/vistagen-to-present-at-psych-congress-fo0nqc165gu1.html

0 · Reply

LewisDaKat Sep. 10 at 3:31 PM

$VTGN Vistagen to Present at Psych Congress 2026 https://marketwirenews.com/stock/vtgn/news/vistagen-to-present-at-psych-congress-2026-8430909190077543.html?utm_source=stocktwits

0 · Reply

To_De_Moon Sep. 10 at 1:52 PM

$VTGN https://x.com/Vistagen/status/2098046548676370438

0 · Reply

Vistagen Therapeutics Transcript: AGM 2026

Sep 10, 2026, 8:30 AM EDT - 3 days ago

Vistagen to Present at Psych Congress 2026

Aug 14, 2026, 8:32 AM EDT - 4 weeks ago

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Aug 14, 2026, 8:30 AM EDT - 4 weeks ago

Vistagen Therapeutics Earnings release: Q1 2027

Aug 14, 2026, 8:30 AM EDT - 4 weeks ago

Vistagen Therapeutics Quarterly report: Q1 2027

2026-08-06T13:45:38.000Z - 5 weeks ago

Vistagen announces topline results from fasedienol repeat dose study

Aug 6, 2026, 8:30 AM EDT - 5 weeks ago

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

2026-08-04T09:10:51.000Z - 5 weeks ago

SRX Global acquires stake in Vistagen

SRXH

Jul 31, 2026, 8:30 AM EDT - 6 weeks ago

Vistagen Appoints Douglas J. Williamson to its Board of Directors

DRUG

Jul 31, 2026, 8:00 AM EDT - 6 weeks ago

Vistagen Therapeutics Proxy statement: Proxy filing

Jul 31, 2026, 8:00 AM EDT - 6 weeks ago

Vistagen Therapeutics Proxy statement: Proxy filing

Jun 30, 2026, 8:30 AM EDT - 2 months ago

Vistagen Therapeutics Transcript: Study update

Jun 30, 2026, 8:30 AM EDT - 2 months ago

Vistagen Therapeutics Press release: Study update

2026-06-30T12:05:47.000Z - 2 months ago

Vistagen announces fasedienol did not achieve primary endpoint

Jun 30, 2026, 8:00 AM EDT - 2 months ago

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Jun 15, 2026, 4:30 PM EDT - 2 months ago

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Jun 15, 2026, 4:00 PM EDT - 2 months ago

Vistagen Therapeutics Earnings release: Q4 2026

Jun 15, 2026, 4:00 PM EDT - 2 months ago

Vistagen Therapeutics Annual report: Q4 2026

2026-06-09T12:37:17.000Z - 3 months ago

Vistagen announces fasedienol achieves minimum patient exposures

Jun 9, 2026, 8:30 AM EDT - 3 months ago

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

May 27, 2026, 8:30 AM EDT - 3 months ago

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

May 20, 2026, 2:35 PM EDT - 3 months ago

Vistagen Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-19T12:37:06.000Z - 3 months ago

Vistagen appoints Angelov as Chief Medical Officer

May 19, 2026, 8:30 AM EDT - 3 months ago

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

May 14, 2026, 8:30 AM EDT - 4 months ago

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

2026-05-12T11:52:14.000Z - 4 months ago

Vistagen reports preliminary positive data on ongoing PALISADE-3 study

May 12, 2026, 7:30 AM EDT - 4 months ago

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

2026-05-08T12:22:06.000Z - 4 months ago

Vistagen announces completion of last patient visit in PALISADE-4 study

May 8, 2026, 7:30 AM EDT - 4 months ago

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

2026-04-22T14:45:36.000Z - 4 months ago

AbCellera target is profile more attractive than Vistagen, says JonesResearch

ABCL

2026-04-22T13:41:58.000Z - 4 months ago

Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing

Apr 22, 2026, 8:30 AM EDT - 4 months ago

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

Mar 17, 2026, 9:00 AM EDT - 6 months ago

Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 3, 2026, 8:30 AM EST - 6 months ago

Vistagen to Participate in Upcoming Investor Conferences

Mar 2, 2026, 3:50 PM EST - 6 months ago

Vistagen Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-25T17:53:19.000Z - 6 months ago

Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims

Feb 25, 2026, 8:30 AM EST - 6 months ago

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Feb 12, 2026, 5:00 PM EST - 7 months ago

Vistagen Therapeutics Earnings Call Transcript: Q3 2026

Feb 12, 2026, 5:00 PM EST - 7 months ago

Vistagen Therapeutics Quarterly report: Q3 2026

Feb 12, 2026, 5:00 PM EST - 7 months ago

Vistagen Therapeutics Earnings release: Q3 2026

Feb 12, 2026, 4:30 PM EST - 7 months ago

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

Feb 6, 2026, 9:52 AM EST - 7 months ago

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Feb 4, 2026, 8:30 AM EST - 7 months ago

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

Jan 22, 2026, 10:45 AM EST - 7 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Jan 16, 2026, 5:06 PM EST - 7 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

2025-12-17T19:25:24.000Z - 9 months ago

Vistagen downgraded to Hold from Buy at Jefferies

2025-12-17T19:25:11.000Z - 9 months ago

Vistagen downgraded to Hold at Jefferies after social anxiety study miss

2025-12-17T17:20:14.000Z - 9 months ago

Vistagen downgraded to Hold from Buy at Maxim

2025-12-17T16:35:29.000Z - 9 months ago

Vistagen downgraded to Market Perform from Outperform at William Blair

2025-12-17T16:35:21.000Z - 9 months ago

Vistagen downgraded to Market Perform at William Blair after PALISADE-3 miss

2025-12-17T15:50:39.000Z - 9 months ago

Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints

2025-12-17T15:45:17.000Z - 9 months ago

Vistagen downgraded to Hold from Buy at Stifel

2025-12-17T14:40:46.000Z - 9 months ago

Vistagen downgraded to Neutral from Buy at Lucid Capital

2025-12-17T14:05:58.000Z - 9 months ago

Vistagen SAD study did not achieve primary endpoint

Dec 17, 2025, 8:30 AM EST - 9 months ago

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Dec 1, 2025, 8:30 AM EST - 9 months ago

Vistagen Appoints Nick Tressler as Chief Financial Officer

Nov 26, 2025, 8:30 AM EST - 9 months ago

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Nov 13, 2025, 5:00 PM EST - 10 months ago

Vistagen Therapeutics Earnings Call Transcript: Q2 2026

Nov 13, 2025, 5:00 PM EST - 10 months ago

Vistagen Therapeutics Quarterly report: Q2 2026

Nov 13, 2025, 5:00 PM EST - 10 months ago

Vistagen Therapeutics Earnings release: Q2 2026

Nov 13, 2025, 4:30 PM EST - 10 months ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 12, 2025, 3:20 PM EST - 10 months ago

Vistagen Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 8:30 AM EST - 10 months ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 3, 2025, 8:30 AM EST - 10 months ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Oct 29, 2025, 8:30 AM EDT - 10 months ago

Vistagen Appoints Paul Edick to its Board of Directors

Oct 16, 2025, 8:30 AM EDT - 11 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Sep 18, 2025, 2:20 PM EDT - 12 months ago

Vistagen Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 12:00 PM EDT - 1 year ago

Vistagen Therapeutics Transcript: AGM 2025

Sep 9, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Quarterly report: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings release: Q1 2026

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Jul 31, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Vistagen Therapeutics Proxy statement: Proxy Filing

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Vistagen Therapeutics Proxy statement: Proxy Filing

Jul 24, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 15, 2025, 8:30 AM EDT - 1 year ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings release: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Annual report: Q4 2025

Jun 17, 2025, 4:30 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 12, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Vistagen Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 8:30 AM EDT - 1 year ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Bulltrader988 Sep. 11 at 7:03 PM

$VTGN Next week 👃👀

0 · Reply

smooth2222 Sep. 11 at 6:47 PM

$VTGN Lets get a buyout for Refisolone, tia, all imo

0 · Reply

defineme44 Sep. 11 at 4:40 PM

0 · Reply

DYL2025 Sep. 11 at 4:29 PM

$VTGN bye bye fuji. hello lilly.

0 · Reply

SpartanTrader117 Sep. 10 at 7:11 PM

$SRXH $VTGN

0 · Reply

gapureau Sep. 10 at 6:56 PM

0 · Reply

MikeScottTradingCo Sep. 10 at 6:33 PM

$VTGN

0 · Reply

Bulltrader988 Sep. 10 at 6:16 PM

0 · Reply

LewisDaKat Sep. 10 at 3:31 PM

$VTGN Vistagen to Present at Psych Congress 2026 https://marketwirenews.com/stock/vtgn/news/vistagen-to-present-at-psych-congress-2026-8430909190077543.html?utm_source=stocktwits

0 · Reply

To_De_Moon Sep. 10 at 1:52 PM

$VTGN https://x.com/Vistagen/status/2098046548676370438

0 · Reply

Gabriel_DS Sep. 10 at 1:14 PM

$VTGN https://finance.yahoo.com/healthcare/articles/vistagen-present-psych-congress-2026-123000345.html

0 · Reply

Diaper_Man Sep. 9 at 7:06 PM

$VTGN Paid propaganda to get you to buy ; Beware young investors Cash, cash equivalents, and marketable securities were $31.7 million as of June 30, 2026. Based on current operating plans, Vistagen believes its cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2027 but are NOT EXPECTED to be SUFFICIENT to extend the Company’s cash runway for more than a year from now. Dilution …. Dilution …. Offering … more dilution … reverse split 100-1 …. NASDAQ noncompliant by (Feb 1)…‼️‼️‼️‼️‼️

0 · Reply

MikeScottTradingCo Sep. 9 at 6:47 PM

$VTGN 200k shares

1 · Reply

nvntr Sep. 9 at 6:02 PM

$VTGN @Diaper_Man Unless you are in a big short position or put and call senario, of if your investment in the stock proved to be to intense for your infantile attitude, it would seem that you have no standing to insert your smelly presence on this site, but we do believe the First Amendment is still in effect and your put down comments are protected , but totally underwhelming. C'est La Vie!

1 · Reply

MikeScottTradingCo Sep. 9 at 5:58 PM

$VTGN

0 · Reply

Diaper_Man Sep. 9 at 4:38 PM

$VTGN 100-1 reverse split coming to you very soon 🤣

0 · Reply

MrZeke Sep. 8 at 4:15 PM

$SRXH I can't believe since June 30 they added these $JMKE $VTGN $CERO Two penny stocks and a sandwich company that offers nothing different than a Subway. Pathetic!

2 · Reply

defineme44 Sep. 8 at 12:26 PM

$VTGN news end of September or early October on menopausal drug. Just keep adding imo but i have feb calls 🚀🚀🚀

1 · Reply

MavrickPete Sep. 7 at 7:53 PM

$VTGN Very severe SAD patients showed nominally significant improvement in PALISADE-4 post-hoc analysis.

0 · Reply

TritiumH3 Sep. 7 at 12:51 AM

$VTGN All in

0 · Reply

To_De_Moon Sep. 4 at 8:11 AM

$VTGN up

1 · Reply

Market Cap	10.52M
Revenue (ttm)	1.27M
Net Income (ttm)	-69.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,487.40%
Debt to Equity Ratio	0.00

Volume	309,900
Avg Vol	3,539,032
Day's Range	N/A - N/A
Shares Out	44.38M
Stochastic %K	23%
Beta	0.39
Analysts	Hold
Price Target	$0.97